FDA extends PDUFA review date for subcutaneous ofatumumab for the treatment of relapsing forms of multiple sclerosis to September 2020.-Novartis.
Genmab A/S announced that the FDA has notified Novartis that the agency has extended its review of the supplemental Biologics License Application (sBLA) for subcutaneous ofatumumab for the… read more.